Seborrhoeic dermatitis

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Retrieved on: 
Saturday, March 9, 2024
The Department, SAN, Immunodeficiency, Psoriasis, Doctor of Philosophy, Waldman, STAT1, IL22, MD, Mount Sinai Health System, Dermatitis, Atopic dermatitis, Biopsy, RNA-Seq, OASL, Rosacea, Laboratory, AAD, CXCL9, FA2H, Hospital, RNA, Immunology, IGA, Patient, Gene, PI3, Seborrhoeic dermatitis, Skin condition, Observational study, Skin, Research, Gene expression, American Academy, Vaccine

“We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.

Key Points: 
  • “We are excited to have successfully employed noninvasive tape-stripping techniques developed from studying these diseases to study an understudied and undertreated inflammatory skin disease, seborrheic dermatitis.
  • These findings will help establish the groundwork for greater understanding of this very common condition.”
    “The pathophysiology of seborrheic dermatitis has been poorly understood.
  • In addition, the skin barrier disruption observed in seborrheic dermatitis has unique molecular underpinnings, primarily in the tight junction of the epithelial skin cells and lipid metabolism pathways.
  • These data demonstrate that seborrheic dermatitis is an immune disease with a uniquely polarized profile distinct from atopic dermatitis and plaque psoriasis.

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Retrieved on: 
Friday, December 15, 2023
Scalp, EST, Seborrhoeic dermatitis, Quality of life, Food, FAAD, Dermatology, Dermatitis, FDA, Success, Itch, Eyelid, Disease, Nose, Social stigma, NDA, MBA, MD, Doctor of Philosophy, Study, Inflammation, Eyebrow, Red, Gel, Week, IGA, Skin, Sleep, Face, Webcast, Human, Patient, Safety, PAP, Pharmaceutical industry

ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Key Points: 
  • ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
  • “Approximately 10 million people in the United States have seborrheic dermatitis, but until today, there have been limited treatment options.
  • In Trial 203, 73% of individuals treated with ZORYVE foam achieved IGA Success (73.1% ZORYVE foam vs 40.8% vehicle; P
  • ZORYVE foam was well-tolerated with a favorable safety and tolerability profile during up to 52 weeks of treatment.

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

Retrieved on: 
Monday, September 25, 2023
Sharon G. Flake, Face, Marketing, FAAD, Embarrassment, Eyebrow, Dermatitis, Patient, Social stigma, Diversity, Weill Cornell Medicine, Inclusion, Diagnosis, Red, Skin, Seborrhoeic dermatitis, Mobile phone, Cosmetics, Dermatology

The campaign, Clearing Up Seb Derm , features expert advice from leading dermatologists and personal stories from individuals living with seborrheic dermatitis.

Key Points: 
  • The campaign, Clearing Up Seb Derm , features expert advice from leading dermatologists and personal stories from individuals living with seborrheic dermatitis.
  • The campaign also aims to raise awareness that Seb Derm symptoms can vary from person to person, may look different across body areas and skin tones, and can sometimes be confused with other skin conditions.
  • “Seborrheic dermatitis is a common inflammatory skin condition that affects an estimated 10 million Americans.
  • “In richly pigmented skin, seborrheic dermatitis can present differently than in lightly pigmented skin.

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Retrieved on: 
Tuesday, April 18, 2023
Human, PDE4, Success, Study, Seborrhoeic dermatitis, Face, NDA, Reduction-sensitive nanoparticles, Scalp, Nose, Dermatitis, Eyebrow, IGA, Eyelid, Phase 3, Dermatology, PDUFA, Itch, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Disease, Pharmaceutical industry, Cosmetics

The application was assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2023.

Key Points: 
  • The application was assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2023.
  • Roflumilast foam was designed to address these shortcomings, as a once-daily, steroid-free topical drug that can be used chronically anywhere on the body.
  • The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was the pivotal Phase 3, parallel group, double-blind, vehicle-controlled study evaluating the safety and efficacy of roflumilast foam 0.3% in seborrheic dermatitis.
  • In addition, 51.3% of individuals in the roflumilast foam treated arm reached complete clearance at Week 8.

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Retrieved on: 
Tuesday, February 21, 2023
Nose, NDA, Week, Eyebrow, Eyelid, Human, Safety, Face, Scalp reduction, Study, Food, Dermatitis, Seborrhoeic dermatitis, Disease, FDA, Scalp, PDE4, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Cosmetics

Arcutis recognizes the urgent need for a new therapy that could enable symptom control, easier management, and increased adherence,” said Patrick Burnett M.D., Ph.D, F.A.A.D., Chief Medical Officer at Arcutis.

Key Points: 
  • Arcutis recognizes the urgent need for a new therapy that could enable symptom control, easier management, and increased adherence,” said Patrick Burnett M.D., Ph.D, F.A.A.D., Chief Medical Officer at Arcutis.
  • “Roflumilast foam, which is being developed as an easy-to-use, steroid free, once-daily topical treatment, has been shown in clinical trials to be effective and well tolerated.
  • “There has not been a once-daily steroid-free topical prescription treatment approved for seborrheic dermatitis in over a decade.
  • The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) was a Phase 3, parallel group, double blind, vehicle-controlled study evaluating the safety and efficacy of roflumilast foam 0.3%.

InventHelp Inventor Develops an Easy Wet Indicating Diaper (DLL-3874)

Retrieved on: 
Tuesday, January 17, 2023
Sale, Joint Medical Service (Germany), Multimedia, Risk, Caregiver, Child, Urinary tract infection, Seborrhoeic dermatitis, Residential care

The patent-pending invention increases convenience for caregivers, as well as the provides the ability to prevent diaper rash and potential urinary tract infections.

Key Points: 
  • The patent-pending invention increases convenience for caregivers, as well as the provides the ability to prevent diaper rash and potential urinary tract infections.
  • Caregivers can check a diaper or pull-up by listening or going near the child or adult, and not risk awakening a sleeping infant or adult.
  • It also saves the task of undressing a fully clothed child or adult in order to check a diaper, pinching the diaper, or inserting a finger inside the diaper.
  • It also helps mask the smell of a wet or dirty diaper in the home or childcare center and can be less humiliating for severely disabled individuals.

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

Retrieved on: 
Friday, October 21, 2022
LinkedIn, The Harris Poll, Disease, Assistant, Population, Conference, Diagnosis, Seborrhoeic dermatitis, Education, Family, Dermatitis, Patient, Income, Twitter, Â, Marital status, Nasdaq, Red, PAS, Practitioner, Sex, Advance for NPs & PAs, Friends, Social stigma, Atopic dermatitis, Awareness, Face, University Challenge 2013–14, Embarrassment, HCP, GLOBE, Jeff Flake, Center, NPS, Scalp, Poster, Health insurance, Medical imaging, Dermatology, Facebook, Dermatology

The survey found that individuals with seborrheic dermatitis often experienced a long and burdensome path to diagnosis, reporting an average of 3.6 years from symptom onset to seeking care, although patients reporting severe disease sought care within 1 year of symptom onset.

Key Points: 
  • The survey found that individuals with seborrheic dermatitis often experienced a long and burdensome path to diagnosis, reporting an average of 3.6 years from symptom onset to seeking care, although patients reporting severe disease sought care within 1 year of symptom onset.
  • In contrast, healthcare providers underestimated the time it takes for people with seborrheic dermatitis to receive a diagnosis, reporting an average of just 1.5 years.
  • According to the survey, individuals with seborrheic dermatitis lacked awareness and education about the disease prior to diagnosis.
  • Arcutis dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and seborrheic dermatitis.

Insights on the White Oil Global Market to 2027 - Featuring Exxon Mobil, HollyFrontier and Sasol Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022
Chemicals, Plastics, Manufacturing, Nitrogen, Tablet, Time, Wax, Garden, Joint, Lip, Seborrhoeic dermatitis, Oil, Growth, Powder, Foundation, Hand, Government, Investment, Excipient, Dermatitis, Joint Medical Service (Germany), Emulsion, Dangerous, Moisturizer, Cosmetics, Color, Nynas

A significant reason driving the growth of the global white oil market is the rising demand for personal care across the world.

Key Points: 
  • A significant reason driving the growth of the global white oil market is the rising demand for personal care across the world.
  • For example, eye makeup remover comprises 99 percent white mineral oil, whereas foundations consist of up to 60 percent white oil.
  • By region, Asia Pacific is expected to hold a notable share in the global white oil market during the forecast period.
  • Due to the rising use of white oil and its derivatives, the Asia Pacific region is expected to witness significant demand for white oil.

New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Friday, September 9, 2022
PDE4, NDA, Safety, IGA, Form 10-K, Dermatitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Study, Time, Doctor of Philosophy, Seborrhoeic dermatitis, Nose, U.S. Securities and Exchange Commission, Risk, Itch, Academy, P92, FAAD, Week, Food, LinkedIn, SEC, Psoriasis, Human, GLOBE, Scalp reduction, Nasdaq, Company, FDA, Atopic dermatitis, Journal of the European Academy of Dermatology and Venereology, Twitter, Face, Congress, Scalp, Eyelid, Eyebrow, Patient, Pharmaceutical industry, Cosmetics, Venereology, Facebook, Dermatology

Roflumilast foam demonstrated strong efficacy across multiple endpoints, including 50% of individuals with seborrheic dermatitis achieving IGA clear at week 8.

Key Points: 
  • Roflumilast foam demonstrated strong efficacy across multiple endpoints, including 50% of individuals with seborrheic dermatitis achieving IGA clear at week 8.
  • Roflumilast foam also demonstrated statistically significant improvements compared to vehicle on all secondary endpoints in the trial, including itch, scaling, and erythema (redness).
  • (63.6% with roflumilast foam vs 42.3% vehicle (P=0.0002))
    More than 50% of individuals treated with roflumilast foam achieved an erythema score of 0 at week 8.
  • Roflumilast foam is a once-daily topical foam formulation of roflumilast which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis.

Triple Paste Announces Partnership with Safe Kids Worldwide

Retrieved on: 
Wednesday, September 7, 2022
Partnership, Burns, Safe Kids Worldwide, Safety, Caregiver, Research, Falls, View, Awareness, Pediatrics, Death, Accident, Parent, Zinc oxide, Skin, Multimedia, Drowning, Seborrhoeic dermatitis, Injury, Mark (given name), Poisoning, Fire, Dermatology, Child, Toy, Instagram, Facebook

CEDAR KNOLLS, N.J., Sept. 7, 2022 /PRNewswire/ -- Triple Paste today announces a partnership with Safe Kids Worldwide to bring awareness around the nonprofit organization and their mission to keep all kids safe from preventable injuries. As a proud sponsor, Triple Paste has provided a generous $50,000 donation towards the cause to help Safe Kids Worldwide protect kids from preventable injuries, the number one cause of death to children in the United States.

Key Points: 
  • CEDAR KNOLLS, N.J., Sept. 7, 2022 /PRNewswire/ -- Triple Paste today announces a partnership with Safe Kids Worldwide to bring awareness around the nonprofit organization and their mission to keep all kids safe from preventable injuries.
  • As a proud sponsor, Triple Paste has provided a generous $50,000 donation towards the cause to help Safe Kids Worldwide protect kids from preventable injuries, the number one cause of death to children in the United States.
  • The partnership will be cross promoted on Triple Paste and Safe Kids Worldwide social platforms to reach a broader audience.
  • With this as a key factor, Triple Paste can help spread the word and safety for children across the U.S. through the Safe Kids Worldwide partnership, research and programs that reach parents, caregivers, children and educators.